151 related articles for article (PubMed ID: 36394890)
1. EFFICACY OF COMBINED SYSTEMIC CORTICOSTEROID AND EARLY IMMUNOMODULATORY THERAPY WITHIN THREE MONTHS OF ONSET IN VOGT-KOYANAGI-HARADA DISEASE.
Park HS; Park HY; Lee CS; Lee SC; Lee JH
Retina; 2022 Dec; 42(12):2361-2367. PubMed ID: 36394890
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
3. Vogt-Koyanagi-Harada Disease Managed With Immunomodulatory Therapy Within 3 Months of Disease Onset.
Ei Ei Lin Oo ; Chee SP; Wong KKY; Hla Myint Htoon
Am J Ophthalmol; 2020 Dec; 220():37-44. PubMed ID: 32738228
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.
Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H
BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758
[TBL] [Abstract][Full Text] [Related]
5. Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.
Herbort CP; Abu El Asrar AM; Yamamoto JH; Pavésio CE; Gupta V; Khairallah M; Tugal-Tutkun I; Soheilian M; Takeuchi M; Papadia M
Int Ophthalmol; 2017 Dec; 37(6):1383-1395. PubMed ID: 27844182
[TBL] [Abstract][Full Text] [Related]
6. Early post-treatment choroidal thickness to alert sunset glow fundus in patients with Vogt-Koyanagi-Harada disease treated with systemic corticosteroids.
Hirooka K; Saito W; Namba K; Mizuuchi K; Iwata D; Hashimoto Y; Ishida S
PLoS One; 2017; 12(2):e0172612. PubMed ID: 28241069
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy.
Alromaih AZ; Almater AI; Albloushi AF; Alkheraiji NF; Abu El-Asrar AM
Int Ophthalmol; 2023 Jan; 43(1):185-195. PubMed ID: 35945413
[TBL] [Abstract][Full Text] [Related]
8. Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease.
Herbort CP; Abu El Asrar AM; Takeuchi M; Pavésio CE; Couto C; Hedayatfar A; Maruyama K; Rao X; Silpa-Archa S; Somkijrungroj T
Int Ophthalmol; 2019 Jun; 39(6):1419-1425. PubMed ID: 29948499
[TBL] [Abstract][Full Text] [Related]
9. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.
Park UC; Cho IH; Lee EK; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438
[TBL] [Abstract][Full Text] [Related]
10. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
12. Acute phase clinical manifestations of patients with Vogt-Koyanagi-Harada disease in Southern China.
Zhang C; Wang Y; Chen Y; Zhou H; Hong Q; Yu X; Ng TK; Cen LP
BMC Ophthalmol; 2023 May; 23(1):199. PubMed ID: 37147563
[TBL] [Abstract][Full Text] [Related]
13. Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; AlBloushi AF; Gikandi PW; Hardarson SH; Stefánsson E
Br J Ophthalmol; 2019 Dec; 103(12):1695-1699. PubMed ID: 30798260
[TBL] [Abstract][Full Text] [Related]
14. Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation.
Keino H; Goto H; Usui M
Graefes Arch Clin Exp Ophthalmol; 2002 Oct; 240(10):878-82. PubMed ID: 12397437
[TBL] [Abstract][Full Text] [Related]
15. A clinical grading system based on ultra-wide field retinal imaging for sunset glow fundus in Vogt-Koyanagi-Harada disease.
Lee EK; Lee SY; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):359-68. PubMed ID: 25017008
[TBL] [Abstract][Full Text] [Related]
16. Vogt-Koyanagi-Harada Syndrome in a Canadian First Nations Population.
Kryshtalskyj MT; Roy M
Ocul Immunol Inflamm; 2022 May; 30(4):894-900. PubMed ID: 33621146
[TBL] [Abstract][Full Text] [Related]
17. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease.
Urzua CA; Velasquez V; Sabat P; Berger O; Ramirez S; Goecke A; Vásquez DH; Gatica H; Guerrero J
Acta Ophthalmol; 2015 Sep; 93(6):e475-80. PubMed ID: 25565265
[TBL] [Abstract][Full Text] [Related]
18. Choroidal observations in Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography.
Nakai K; Gomi F; Ikuno Y; Yasuno Y; Nouchi T; Ohguro N; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2012 Jul; 250(7):1089-95. PubMed ID: 22240936
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study.
Nakai S; Takeuchi M; Usui Y; Namba K; Suzuki K; Harada Y; Kusuhara S; Kaburaki T; Tanaka R; Takeuchi M; Mizuki N; Nakai K; Goto H; Herbort CP
Ocul Immunol Inflamm; 2024 May; 32(4):367-375. PubMed ID: 35748779
[TBL] [Abstract][Full Text] [Related]
20. Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up.
Herbort CP; Mantovani A; Bouchenaki N
Int Ophthalmol; 2007; 27(2-3):173-82. PubMed ID: 17457515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
